TransMedics Group, Inc. (TMDX) saw its stock price soar 6.12% in the pre-market trading session on Tuesday, following the company's robust response to an inaccurate and misleading short-seller report issued by Scorpion Capital.

TransMedics vehemently denied the claims made in the report, asserting that it failed to accurately represent the company's business, technology, and focus on delivering products and services for organ transplantation. The company highlighted that its OCS technology and NOP program have enabled over 7,000 organ transplants, allowing surgeons to utilize donor organs that would have otherwise been unutilized. TransMedics defended the integrity of its practices, team, compliance, and commitment to improving clinical outcomes.

The company's technology and services have driven an expansion in overall U.S. transplant volumes and exceptional post-transplant clinical outcomes, as validated by its extensive clinical data set. Investors appear to be responding positively to TransMedics' strong rebuttal and reiteration of its growth prospects.